Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression

Experimental Physiology

Volumn 93, Issue 5, 2008, Pages 622-630

  Burchill, L ^a   Velkoska, E ^a   Dean, R G ^a   Lew, R A ^b   Smith, A I ^b   Levidiotis, V ^c   Burrell, L M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; RAMIPRIL;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERTENSION; KIDNEY INJURY; NEPHRECTOMY; NONHUMAN; POLYURIA; PROTEIN EXPRESSION; PROTEINURIA; RAT;

EID: 42649091118     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.040386     Document Type: Article

References (35)

1. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, Ehmke H, Mall G & Ritz E (1998a). Cardiac remodelling in experimental renal failure—an immunohistochemical study. Nephrol Dial Transplant 13, 1958–1966.
2. Amann K, Rychlik I, Miltenberger‐Milteny G & Ritz E (1998b). Left ventricular hypertrophy in renal failure. Kidney Int Suppl 68, S78–S85.
3. Averill DB, Ishiyama Y, Chappell MC & Ferrario CM (2003). Cardiac angiotensin‐(1–7) in ischemic cardiomyopathy. Circulation 108, 2141–2146.
4. Brilla CG, Zhou G, Matsubara L & Weber KT (1994). Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26, 809–820.
5. Burrell LM, Johnston CI, Tikellis C & Cooper ME (2004). ACE2, a new regulator of the renin‐angiotensin system. Trends Endocrinol Metab 15, 166–169.
6. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME & Johnston CI (2005). Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26, 369–375 ; discussion 322–324.
7. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME & Burrell LM (2003). A breaker of advanced glycation end products attenuates diabetes‐induced myocardial structural changes. Circ Res 92, 785–792.
8. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME & Gilbert RE (2001). Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60, 715–721.
9. Cao Z, Cooper ME, Wu LL, Cox AJ, Jandeleit‐Dahm K, Kelly DJ & Gilbert RE (2000). Blockade of the renin‐angiotensin and endothelin systems on progressive renal injury. Hypertension 36, 561–568.
10. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira‐dos‐Santos AJ, Da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y & Penninger JM (2002). Angiotensin‐converting enzyme 2 is an essential regulator of heart function. Nature 417, 822–828.
11. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD & Patane MA (2002). Substrate‐based design of the first class of angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 124, 11852–11853.
12. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM & Burrell LM (2005). Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 53, 1245–1256.
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE & Acton S (2000). A novel angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87, E1–E9.
14. Duncan AM, Burrell LM, Kladis A & Campbell DJ (1996). Effects of angiotensin‐converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 28, 746–754.
15. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlof B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K & De Zeeuw D (2007). Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 25, 871–876.
16. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH & Diz DI (2002). Vasopeptidase inhibition and Ang‐(1–7) in the spontaneously hypertensive rat. Kidney Int 62, 1349–1357.
17. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI & Gallagher PE (2005). Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation 111, 2605–2610.
18. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC & Barre PE (1995). Clinical and echocardiographic disease in patients starting end‐stage renal disease therapy. Kidney Int 47, 186–192.
19. Foley RN, Parfrey PS & Sarnak MJ (1998). Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32, S112–S119.
20. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK & Katovich MJ (2007). Prevention of angiotensin II‐induced cardiac remodeling by angiotensin‐(1–7). Am J Physiol Heart Circ Physiol 292, H736–H742.
21. Grobe JL, Mecca AP, Mao H & Katovich MJ (2006). Chronic angiotensin‐(1–7) prevents cardiac fibrosis in DOCA‐salt model of hypertension. Am J Physiol Heart Circ Physiol 290, H2417–H2423.
22. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM & Raizada MK (2005). Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90, 783–790.
23. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX & Greenberg BH (2005). Angiotensin‐(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289, H2356–2363.
24. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE & Hsueh WA (2000). Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101, 1130–1137.
25. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z & Shapiro JI (2003). Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 14, 90–97.
26. Lee AA, Dillmann WH, McCulloch AD & Villarreal FJ (1995). Angiotensin II stimulates the autocrine production of transforming growth factor‐β1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 27, 2347–2357.
27. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ & Jaber BL (2006). Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 1, 43–51.
28. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J & Cooper ME (2003). Characterization of renal angiotensin‐converting enzyme 2 in diabetic nephropathy. Hypertension 41, 392–397.
29. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F & Garg AX (2006). Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17, 2034–2047.
30. Tornig J, Amann K, Ritz E, Nichols C, Zeier M & Mall G (1996). Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7, 667–675.
31. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A & Tummino P (2002). Hydrolysis of biological peptides by human angiotensin‐converting enzyme‐related carboxypeptidase. J Biol Chem 277, 14838–14843.
32. Wilk S & Orlowski M (1983). Inhibition of rabbit brain prolyl endopeptidase by n‐benzyloxycarbonyl‐prolyl‐prolinal, a transition state aldehyde inhibitor. J Neurochem 41, 69–75.
33. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME & Gilbert RE (1997). Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin‐angiotensin system. Kidney Int 51, 1553–1567.
34. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, Tatara Y, Shiota A, Sugano S, Takeda S, Rakugi H & Ogihara T (2006). Deletion of ACE2 accelerates pressure overload‐induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 1–10.
35. Zulli A, Burrell LM, Widdop RE, Black MJ, Buxton BF & Hare DL (2006). Immunolocalization of ACE2 and AT 2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem 54, 147–150.